year 18, Issue 1 (January - February 2024)
Iran J Med Microbiol 2024, 18(1): 8-15 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohammad Rezakhani O, Farzin D, Farrokhfar S, Darban Razavi E, Vahdatinia A, Azadtarigheh P et al . Assessment of the Stability of Pseudomonas aeruginosa-specific Myoviridae Bacteriophages in Mupirocin and Abukhalsa Burnt Ointments. Iran J Med Microbiol 2024; 18 (1) :8-15
URL: http://ijmm.ir/article-1-2283-en.html
URL: http://ijmm.ir/article-1-2283-en.html
Omid Mohammad Rezakhani1 
, Davood Farzin2 
, Samaneh Farrokhfar3 , Erfan Darban Razavi1 , Alireza Vahdatinia4 , Parnian Azadtarigheh5 , Bahareh Lashtoo Aghaee6
, Davood Farzin2 , Samaneh Farrokhfar3 , Erfan Darban Razavi1 , Alireza Vahdatinia4 , Parnian Azadtarigheh5 , Bahareh Lashtoo Aghaee6
1- Department of Pharmacy, Ramsar Campus, Mazandaran University of Medical Sciences, Ramsar, Iran
2- Department of Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
3- Department of Anatomical Sciences, Faculty of Medicine, Ramsar Campus, Mazandaran University of Medical Sciences, Ramsar, Iran
4- Student Research Committee, Mazandaran University of Medical Sciences Faculty of Medicine, Sari, Iran
5- Department of Medicine, Faculty of Medicine, Ramsar Campus, Mazandaran University of Medical Sciences, Ramsar, Iran
6- Department of Microbiology, Faculty of Medicine, Ramsar Campus, Mazandaran University of Medical Sciences, Ramsar, Iran ,b.aghaee@hotmail.com
2- Department of Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
3- Department of Anatomical Sciences, Faculty of Medicine, Ramsar Campus, Mazandaran University of Medical Sciences, Ramsar, Iran
4- Student Research Committee, Mazandaran University of Medical Sciences Faculty of Medicine, Sari, Iran
5- Department of Medicine, Faculty of Medicine, Ramsar Campus, Mazandaran University of Medical Sciences, Ramsar, Iran
6- Department of Microbiology, Faculty of Medicine, Ramsar Campus, Mazandaran University of Medical Sciences, Ramsar, Iran ,
Abstract: (1180 Views)
Background and Aim: Antibiotic resistance in bacterial infections poses a global health crisis, leading to over 1.27 million annual global deaths in 2019. Pseudomonas aeruginosa is the major cause of healthcare-associated infections, particularly in severe burn cases. The use of lytic phages in a mono- or combination therapy with antibiotics, can be helpful to combat antimicrobial-resistant infections in burn wound patients. This study explores stability in mupirocin and Abukhalsa of three P. aeruginosa-specific characterized and annotated phages (PA45, PA32, PA6) belonging to the Myoviridae group.
Materials and Methods: Each phage was mixed with the mupirocin and Abukhalsa and incubated for 2, 4, and 24 hours at 37°C, with quantification using the agar-overlay method. The results were measured with a one-way analysis of variance statistical method (ANOVA) followed by Holm-Sidak's multiple comparisons test.
Results: The study shows that all three phages were stable above the effective therapeutic titer (ETT) which is considered >107 pfu/mL, with mupirocin more affecting phage activity and retaining efficacy after 24 hours. Notably, Abukhalsa inhibited phage activity even though phages remained active above the ETT after 24 hours.
Conclusion: This study highlights the suitability of mupirocin and Abukhalsa ointments for the studied phages, sustaining their activity beyond the ETT for 24 hours. PA6 and PA32 (jumbo phage) were more stable than PA45 in both ointments tested. These findings emphasize the potency of further investigations for an effective topical combination treatment option in burn wound infections.
Type of Study: Original Research Article |
Subject:
Medical Bacteriology
Received: 2023/12/2 | Accepted: 2024/01/29 | ePublished: 2024/03/18
Received: 2023/12/2 | Accepted: 2024/01/29 | ePublished: 2024/03/18
References
1. Flynn CE, Guarner J. Emerging Antimicrobial Resistance. Mod Pathol. 2023;36(9):100249. [DOI:10.1016/j.modpat.2023.100249] [PMID]
2. Ranjbar R, Alam M. Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Evid.-Based Nurs. 2024;27(1):16. [DOI:10.1136/ebnurs-2022-103540] [PMID]
3. Reig S, Le Gouellec A, Bleves S. What Is New in the Anti-Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?. Front Cell Infect Microbiol. 2022;12:909731. [DOI:10.3389/fcimb.2022.909731] [PMID] [PMCID]
4. Jurado-Martín I, Sainz-Mejías M, McClean S. Pseudomonas aeruginosa: An audacious pathogen with an adaptable arsenal of virulence factors. Int J Mol Sci. 2021;22(6):3128. [DOI:10.3390/ijms22063128] [PMID] [PMCID]
5. Aghaee BL, Khan Mirzaei M, Alikhani MY, Mojtahedi A, Maurice CF. Improving the inhibitory effect of phages against Pseudomonas aeruginosa isolated from a burn patient using a combination of phages and antibiotics. Viruses. 2021;13(2):334. [DOI:10.3390/v13020334] [PMID] [PMCID]
6. Wu DC, Chan WW, Metelitsa AI, Fiorillo L, Lin AN. Pseudomonas skin infection: clinical features, epidemiology, and management. Am J Clin Dermatol. 2011;12:157-69. [DOI:10.2165/11539770-000000000-00000] [PMID]
7. Reynolds D, Kollef M. The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update. Drugs. 2021;81(18):2117-31. [DOI:10.1007/s40265-021-01635-6] [PMID] [PMCID]
8. Marcus JE, Chung KK, Blyth DM. Burn Wound Infection. In Essential Burn Care for Non-Burn Specialists 2023 Jul 20 (pp. 213-231). Cham: Springer International Publishing. [DOI:10.1007/978-3-031-28898-2_9]
9. Lashtoo Aghaee B, Alikhani M Y, van Leeuwen W B, Mojtahedi A, Kazemi S, Karami P. Conventional Treatment of Burn Wound Infections versus Phage Therapy. Iran J Med Microbiol. 2022;16(3):186-96. [DOI:10.30699/ijmm.16.3.186]
10. Skowrońska W, Bazylko A. The Potential of Medicinal Plants and Natural Products in the Treatment of Burns and Sunburn-A Review. Pharmaceutics. 2023;15(2):633. [DOI:10.3390/pharmaceutics15020633] [PMID] [PMCID]
11. Marashi SM, Nikkhahi F, Hamedi D, Shahbazi G. Isolation, Characterization and in vitro Evaluation of Specific Bacteriophages Targeting Extensive Drug Resistance Strains of Pseudomonas aeruginosa Isolated from Septic Burn Wounds. Infect Chemother. 2022;54(1):153-64. [DOI:10.3947/ic.2021.0132] [PMID] [PMCID]
12. Merabishvili M, Monserez R, Van Belleghem J, Rose T, Jennes S, De Vos D, et al. Stability of bacteriophages in burn wound care products. PLoS One. 2017;12(7):e0182121. [DOI:10.1371/journal.pone.0182121] [PMID] [PMCID]
13. Hatfull GF, Dedrick RM, Schooley RT. Phage Therapy for Antibiotic-Resistant Bacterial Infections. Annu Rev Med. 2022;73:197-211. [DOI:10.1146/annurev-med-080219-122208] [PMID]
14. Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS. Antibiotic resistance and persistence-Implications for human health and treatment perspectives. EMBO reports. 2020;21(12):e51034. [DOI:10.15252/embr.202051034] [PMID] [PMCID]
15. Chegini Z, Khoshbayan A, Taati Moghadam M, Farahani I, Jazireian P, Shariati A. Bacteriophage therapy against Pseudomonas aeruginosa biofilms: A review. Ann Clinical Microbiol Antimicrob. 2020;19:1-7. [DOI:10.1186/s12941-020-00389-5] [PMID] [PMCID]
16. Jończyk-Matysiak E, Łodej N, Kula D, Owczarek B, Orwat F, Międzybrodzki R, et al. Factors determining phage stability/activity: Challenges in practical phage application. Expert Rev Anti-infect Ther. 2019;17(8):583-606. [DOI:10.1080/14787210.2019.1646126] [PMID]
17. Sutherland R, Boon RJ, Griffin KE, Masters PJ, Slocombe B, White AR .Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985;27(4): 495-8. [DOI:10.1128/AAC.27.4.495] [PMID] [PMCID]
18. Ward A, Campoli-Richards DM. Mupirocin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1986;32:425-44. [DOI:10.2165/00003495-198632050-00002] [PMID]
19. Parenti MA, Hatfield SM, Leyden JJ. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm. 1987;6(10):761-770.
20. Bryskier A. Mupirocin In: Bryskier A, editor. Antimicrobial agents. ASM Press: American Society for Microbiology; 2005. pp 964-71. [DOI:10.1128/9781555815929.ch36]
21. Bryskier A. Peptide antibiotics In: Bryskier A, editor. Antimicrobial agents. ASM Press: American Society for Microbiology; 2005. pp. 826-79. [DOI:10.1128/9781555815929.ch30]
22. Ashkani-Esfahani S, Imanieh MH, Khoshneviszadeh M, Meshksar A, Noorafshan A, Geramizadeh B, et al. The healing effect of arnebia euchroma in second degree burn wounds in rat as an animal model. Iran Red Crescent Med J. 2012;14(2):70-4.
23. Nasiri E, Hosseinimehr SJ, Azadbakht M, Akbari J, Enayati-Fard R, Azizi S, et al. The Healing Effect of Arnebia Euchroma Ointment versus Silver Sulfadiazine on Burn Wounds in Rat. World J Plast Surg. 2015;4(2):134-44. [DOI:10.1515/jcim-2014-0068] [PMID]
24. Mangalea MR, Duerkop BA. Fitness Trade-Offs Resulting from Bacteriophage Resistance Potentiate Synergistic Antibacterial Strategies. Infect Immun. 2020;88(7):e00926-19. [DOI:10.1128/IAI.00926-19] [PMID] [PMCID]
25. Laure NN, Ahn J. Phage resistance-mediated trade-offs with antibiotic resistance in Salmonella Typhimurium. Microb Pathog. 2022;171:105732. [DOI:10.1016/j.micpath.2022.105732] [PMID]
26. Fujiki J, Nakamura K, Nakamura T, Iwano H. Fitness Trade-Offs between Phage and Antibiotic Sensitivity in Phage-Resistant Variants: Molecular Action and Insights into Clinical Applications for Phage Therapy. Int J Mol Sci. 2023;24(21):15628. [DOI:10.3390/ijms242115628] [PMID] [PMCID]
27. Van Nieuwenhuyse B, Van der Linden D, Chatzis O, Lood C, Wagemans J, Lavigne R, et al. Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler. Nat Commun. 2022;13(1):5725. [DOI:10.1038/s41467-022-33294-w] [PMID] [PMCID]
28. Hasan M, Dawan J, Ahn J. Assessment of the potential of phage-antibiotic synergy to induce collateral sensitivity in Salmonella Typhimurium. Microb Pathog. 2023;180:106134. [DOI:10.1016/j.micpath.2023.106134] [PMID]
29. Majkowska-Skrobek G, Markwitz P, Sosnowska E, Lood C, Lavigne R, Drulis-Kawa Z. The evolutionary trade-offs in phage-resistant Klebsiella pneumoniae entail cross-phage sensitization and loss of multidrug resistance. Environ Microbiol. 2021;23(12):7723-40. [DOI:10.1111/1462-2920.15476] [PMID]
30. Burmeister AR, Fortier A, Roush C, Lessing AJ, Bender RG, Barahman R, et al. Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance. Proc Natl Acad Sci U S A. 2020;117(21):11207-16. [DOI:10.1073/pnas.1919888117] [PMID] [PMCID]
31. Burmeister AR, Turner PE. Trading-off and trading-up in the world of bacteria-phage evolution. Curr Biol. 2020;30(19):R1120-R4. [DOI:10.1016/j.cub.2020.07.036] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
Iranian Journal of Medical Microbiology by Farname is licensed under CC BY-NC 4.0
